secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2021-10-25T23:59:59+00:00
Accession:  0001493152-21-026238
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrity Applications appoints Paul Goode as President and COO effective Nov 1, 2021
--------------------------------------------------------------------------------

- Paul V. Goode appointed President and COO effective November 1, 2021; steps down from Board.
- Base salary of $175,000/year; eligible for cash bonus up to 20% of base salary.
- Granted options to purchase 1.5% of fully diluted common stock at exercise price ≥ $5.20, vesting over 3 years.
- Goode most recently VP of Product Development at Orchestra Biomed; will lead U.S. infrastructure for GlucoTrack trials.
- Employment agreement includes standard termination provisions and financial-misstatement clawback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315221026238/0001493152-21-026238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315221026238/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-026238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer